KD Logo

A company insider recently sold 30,000 shares of Day One Biopharmaceuticals Inc [DAWN]. Should You Sale?

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Day One Biopharmaceuticals Inc shares valued at $378,588 were sold by Blackman Samuel C. on Jun 10 ’24. At $12.62 per share, Blackman Samuel C. sold 30,000 shares. The insider’s holdings dropped to 1,141,081 shares worth approximately $14.97 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Bender Jeremy sold 7,873 shares, netting a total of over 126,588 in proceeds. Following the sale of shares at $16.08 each, the insider now holds 654,728 shares.

Before that, Dubow Adam had sold 3,253 shares from its account. In a trade valued at $52,304, the GENERAL COUNSEL traded Day One Biopharmaceuticals Inc shares for $16.08 each. Upon closing the transaction, the insider’s holdings decreased to 3,253 shares, worth approximately $0.29 million.

As published in a research note from Needham on April 24, 2024, Day One Biopharmaceuticals Inc [DAWN] has been retained to a Buy and the price target has been revised to $33. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”an Underperform”‘ outlook in a report released in late April. As of February 08, 2023, CapitalOne has initiated its “an Overweight” rating for DAWN. Earlier on February 03, 2023, Oppenheimer initiated its rating. Their recommendation was “a Perform” for DAWN stock.

Analyzing DAWN Stock Performance

During the last five days, there has been a surge of approximately 0.92%. Over the course of the year, Day One Biopharmaceuticals Inc shares have dropped approximately -10.14%. Shares of the company reached a 52-week high of $18.07 on 05/01/24 and a 52-week low of $11.94 on 06/17/24. A 50-day SMA is recorded $14.71, while a 200-day SMA reached $13.88. Nevertheless, trading volume fell to 0.86 million shares from 1.29 million shares the previous day.

Support And Resistance Levels for Day One Biopharmaceuticals Inc (DAWN)

According to the 24-hour chart, there is a support level at 12.83, which, if violated, would cause prices to drop to 12.55. In the upper region, resistance lies at 13.50. The next price resistance is at 13.89. RSI (Relative Strength Index) is 44.77 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.01, which suggests the price will decrease in the coming days. Percent R is at 40.70%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Which companies own the most shares of Day One Biopharmaceuticals Inc (DAWN)?

On December 15, 2022, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $35.

Most Popular